Gabapentin Treatment of Cannabis Dependence

Status Completed

Clinical Trial Summary

This is a clinical study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.

Clinical Trial Description

This is a 12-week, double blind, placebo controlled study to evaluate the efficacy of gabapentin in treating outpatients with cannabis dependence. After an initial phone screen, a comprehensive screening visit is scheduled to determine eligibility. Baseline assessments using measurement instruments are conducted on cannabis use, neuropsychological functioning, withdrawal, craving, pain, mood and sleep. Upon enrollment, counseling, medication dispensation and research assessments occur 1 time per week for 3 months and include assessments in withdrawal, craving, pain, mood and sleep. A final, follow-up visit occurs at the end of the 3 months. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00974376
Study type	Interventional
Source	The Scripps Research Institute
Contact
Status	Completed
Phase	Phase 2
Start date	August 2009
Completion date	May 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01005810` - A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana	Phase 2
Completed	`NCT00114439` - Lithium Cannabis Withdrawal Study	Phase 2
Completed	`NCT00350285` - The Teen Marijuana Check-Up	Phase 2
Completed	`NCT01618656` - Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal	Phase 2
Completed	`NCT01153490` - Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine	Phase 4
Completed	`NCT02946489` - Facilitating the Behavioral Treatment of Cannabis Use Disorder	Phase 1
Completed	`NCT02088177` - Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence	Phase 1/Phase 2
Not yet recruiting	`NCT01565174` - The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis	N/A
Completed	`NCT01697709` - Quetiapine Pharmacotherapy for Cannabis Dependence	Phase 2
Recruiting	`NCT04721353` - Reducing Cannabis Overuse With Prazosin	Phase 4
Completed	`NCT01603992` - Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
Completed	`NCT00167297` - Atomoxetine for the Treatment of Cannabis Dependence	Phase 2
Terminated	`NCT01598896` - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia	Phase 2/Phase 3
Completed	`NCT01611948` - Treatment for Cannabis Withdrawal and Dependence	Phase 2
Recruiting	`NCT03221231` - N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms	Phase 4
Not yet recruiting	`NCT03366909` - Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness	N/A
Completed	`NCT01639872` - Clozapine for Cannabis Use in Schizophrenia	Phase 4
Not yet recruiting	`NCT06334016` - Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream	Early Phase 1
Completed	`NCT01793961` - Effects of Chronic Intake of Cannabis on Contrast Sensitivity	N/A
Completed	`NCT01747850` - Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence	Phase 2